Our multifunctional nano-technology carrier platform harnesses the physical (magnetic, electromagnetic and acoustic)and chemical properties of graphene to generate a diversified product pipeline for diagnostic, therapeutic and regenerative medicine. Graphene's properties "actively" enhances the overall attributes of the constructs rather than serving as a passive carrier.

 

 

Fundamental Attributes of Our Platforms:

 

• Versatile carrier or scaffold for variety of medical interesting atoms and molecules. 

• Allows multi-modal clinical and molecular imaging over various length and time scales.

• Facilates stimulus responsive therapeutics and tissue engineering. 

 

 

ManGraDex

​

PLATFORM VALUE PROPOSITION:

• Modular platform for multimodal clinical and molecular imaging.

• Detectable by magnetic resonance, photoacoustic, and Raman imaging.

• Suitable for whole body screening of vital organs or vascular imaging.

• Could facilitate improved image-guided pre-operative staging and intraoperative procedures (e.g. cancer staging and resection).

 

CURRENT STATUS:

• Conducting investigational new drug (IND)- enabling preclinical studies to assess its efficacy as a long circulating MRI contrast agent for unserved and underserved renal and cardiovascular patient population. 

• Conducting preclinical studies to assess its efficacy  for photoacoustic imaging of sentinel lymph nodes for breast cancer.

• Conducting preclinical studies to assess its efficacy for molecular breast cancer screening by MRI (significantly improved specificity).

​

​

​

​

​

​

Nano-GenXb

PLATFORM VALUE PROPOSITION:

• Modular platform for image-guided drug and gene delivery.

• Promotes multivalent ligand−cell receptor interactions for enhanced delivery.

• Allows increased drug or gene-loading capacity.

• Facilitates stimulus-responsive controlled drug or gene release inside target cells.

• Enables real-time tracking by multimodal imaging systems.

 

CURRENT STATUS:

• Completed non-GLP safety pharmacology studies in small animals.

• Scale up and GLP manufacturing in progress.

• GLP safety pharmacology studies planned in first quarter of 2017.

• Conducting preclinical efficacy studies for image-guided delivery of drugs for human papiloma virus (HPV)-induced head and neck cancer.

​

COLLABORATORS:

• Dr. John Haley and Dr. Kenneth Shroyer, Stony Brook University
  Conducting preclinical efficacy studies for image-guided delivery of CRISPR/Cas9 constructs to treat Herpesvirus infections.

• Dr. Laurie Krug, Stony Brook University
  Conducting preclinical efficacy studies for image-guided delivery of
  microRNAs to treat breast cancer metastases.

• Dr. Vivek Mittal, Weill Cornell and Mircan Therapeutics 
  Conducting preclinical efficacy studies for image-guided delivery of myelin

      basic protein nucleic acid therapeutics to treat Alzheimer’s disease.

• Dr. William Van Nostrond, Stony Brook University and Gyrus Pharmaceuticals

​

​

​

​

​

​

GraFix

PLATFORM VALUE PROPOSITION:

• Modular three dimensional all carbon implantable graft substitute (porous scaffold) for tissue engineering.

• Generates biophysical stimulus, rather than biochemical cue to affect the differentiation of stem cells.

• Facilitates controlled release of biologics into the regenerating tissue.

• Allows real time monitoring of anatomical and physiological changes during the tissue regeneration process by multimodal imaging.

 

CURRENT STATUS:

• Conducting preclinical studies to assess its safety and efficacy as a stimulus-responsive tissue engineering scaffold to treat and monitor the process of regeneration in open fractures. 

• Conducting preclinical studies to assess its safety and efficacy as a as a stimulus-responsive tissue engineering scaffold to treat and monitor the process of regeneration in burn wounds.